共 89 条
[1]
Han R(2019)Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update BMC Infect Dis 19 655-145
[2]
Zhou J(2018)The impact of treatment of hepatitis C with DAAs on the occurrence of HCC Liver Int 38 139-1218
[3]
François C(2020)Virological and clinical outcome of DAA containing regimens in a cohort of patients in Calabria Region (Southern Italy) Medicina (Kaunas) 56 101-98
[4]
Roche B(2020)EASL recommendations on treatment of hepatitis C: final update of the series☆ J Hepatol 73 1170-1130
[5]
Coilly A(2022)Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents Sci Rep 12 193-1325
[6]
Duclos-Vallee V(2022)Non-invasive evaluation of liver fibrosis changes in patients with chronic hepatitis C after directly acting antiviral drugs Afro-Egyptian Journal of Infectious and Endemic Diseases 12 92-526
[7]
Scaglione M(2022)Fibrosis regression following hepatitis C antiviral therapy World J Hepatol 14 1120-e122
[8]
Mazzitelli C(2006)Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection Hepatology (Baltimore, MD) 43 1317-242
[9]
Costa HW(2003)A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology (Baltimore, MD) 38 518-38
[10]
Yoo T(2014)Which are the cut-off values of 2D-shear wave elastography (2D-SWE) liver stiffness measurements predicting different stages of liver fibrosis, considering transient elastography (TE) as the reference method? Eur J Radiol 83 e118-739